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Review Paper 
The bacterial ghost (BG) system represents a novel 
and progres­sive approach in the development of 
bacterial mediated cancer immunotherapy. The 
empty inner space of BGs can be filled with drugs, 
proteins, DNA, enzymes and other compounds. The 
induced lysis process does not harm the essential 
structural components of the bacteria, giving rise to 
immunologically active particles capable of 
stimulating the host immune system and delivering 
specific antigen (Ag) to professional antigen-
presenting cells (APCs) or active substances to the 
target cells (1,2). 
Despite the large number of various anti-cancer drugs on the market, proper 
delivery systems are needed to decrease serious toxic and non-curative side 
effects. In order to enhance compliance, several delivery systems such as 
polymeric micro- and nanoparticles, liposomal systems and erythrocyte 
ghosts have been developed. Bacterial ghosts (BGs) represent novel 
advanced delivery and targeting vehicles suitable for delivery of hydrophobic 
or water-soluble drugs. BGs are empty bacterial envelopes of Gram-negative 
bacteria produced by controlled expression of cloned gene E, forming a lysis 
tunnel structure within the envelope of the living bacteria. BGs are devoid of 
cytoplasmic content and possess all bacterial bio-adhesive surface properties 
in their original state while not posing any infectious threat. BGs are ideally 
suited as an advanced drug delivery system for toxic substances in tumor 
therapy. The inner space of BGs can be loaded with either single components 
or combinations of peptides, drugs or DNA which provides an opportunity to 
design new types of (polyvalent) drug delivery vehicles. 
In particular, Doxorubicin-loaded bacterial ghosts have been used to target 
colon carcinoma cells. DOX, a cytotoxic drug commonly used in cancer 
therapy, was used as a model substance to demonstrate the delivery of 
moderate water-soluble drugs by BGs. The application of DOX with BGs 
increased the efficacy of treatment by two folds. The same effect was 
observed after incubation of leukemia cells and melanoma cells with DOX 
loaded BGs. 
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Production of bacterial ghosts 
BGs are produced by expression of cloned gene E 
from bacteriophage ϕX174 resulting to cell lysis in 
Gram-negative bacteria, such as, Escherichia coli 
K12 strains, Klebsiella pneu­moniae, Mannheimia 
(Pasteurella) haemolytica, Neisseria menin­gitidis, 
Salmonella typhimurium, Vibrio cholera, 
Helicobacter pylori, and others (3,4). Expression of 
gene E can be placed under transcriptional control of 
either the thermo sensitive EpL/pR-cI857 promoter, 
or under chemical inducible promoter repressor 
systems, like lacPO or the tol expression system. 
Gene E codes for 91 amino acids and exerts its lytic 
function by fusion of the inner and outer cell 
membranes, forming a specific transmembrane 
tunnel structure through which all the cytoplasmic 
content is expelled, thus leaving a bacterial envelope 
called a BG devoid of nucleic acids, ribosomes and 
other intracel­lular constituents. The inner 
membrane (IM) and outer membrane (OM) 
structures of BGs remain intact during the lysis 
process (5,6). Electron micros­copy studies and 
enzymatic studies clearly showed a sealed 
periplasmic space at the border of the lysis tunnel. 
The efficiency of the E-mediated lysis process, and 
quan­tification of generated BGs and non lysed 
viable bacteria are determined by flow cytometry 
assays using a specific dye that is sensitive to the 
changes of discriminatory power of membrane 
potential and stains only cells that have lost  
membrane poten­tial (BGs or dead bacteria). 
 
 Bacterial ghosts as advanced drug delivery 
systems 
Many diseases including cancers require the 
systemic administration of highly aggressive drugs 
to already immunocompromised patients. 
Deleterious and often severe side effects result from 
a lack of cellular and tissue selectivity. Another 
major issue is the poor solubility of some drugs used 
in cancer treatment. Considering these limitations, 
the development of a safer and more efficient drug 
delivery system (DDS) is the priority for future 
advanced cancer treatments (7). 
Recently, bacterial ghosts made from the colonic 
commensal Mannheimia haemolytica were used for 
in vitro delivery of doxorubicin (DOX) to human 
colorectal adenocarcinoma (Caco-2) cells. 
Adherence studies showed that the M. haemolytica 
ghosts targeted the Caco-2 cells and released the 
loaded DOX within the cells. Cytotoxicity assays 
showed a two folds enhancement in cytotoxic and 
anti-proliferative activity in cells incubated with 
DOX-loaded ghosts as compared with cells for 
which DOX was directly added to the culture media 
(8). This phenomenon might be caused by 
degradation of DOX-loaded BGs within the endo-
lysosome of target cells allowing DOX to bypass the 
multi-drug resistance (MDR) efflux pumps and 
resulting in enhanced accumulation of DOX in the 
cytoplasm and then in the nuclear area of target 
cells. 
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 Current work with bacterial ghosts lies in the 
investigation of the carrier capacity of the 
cytoplasmic lumen. This intracellular space of BGs 
can be filled either with water-soluble substances or 
emulsions such that the drug(s) of interest can be 
coupled to streptavidin anchored on the inside of the  
cytoplasmic  membrane. Moreover, bacterial ghosts 
can be filled and sealed for the delivery of fluid, non
-anchored substances. In a recent study, E. coli 
ghosts were filled with the reporter substance calcein 
and were sealed by fusion with membrane vesicles 
to maintain inner membrane integrity. Adherence 
and uptake studies showed that murine macrophages 
and human Caco-2 cells took up the bacterial ghosts, 
and calcein was released within the cells (1,7,9). 
 
Bacterial ghosts as immunologically active 
particles 
Because of the unique structure of the BG’s 
envelope with preserved pathogen-associated 
molecular patterns (PAMPs), BGs can be used in 
biomedicine alone as an adjuvant or as a delivery 
vehicle for drugs or genes. The inner space of BG’s 
empty envelope can be loaded with a combination of 
peptides, drugs or foreign DNA which gives us an 
opportunity to design new types of polyvalent 
vaccines (9). BGs have excellent DNA loading 
capacity varying from 4000 to 6000 plasmid copies 
per BG depending on the concentrations of DNA 
solution used (10-13). BGs loaded with plasmid 
DNA are efficiently internalized and phagocytozed 
by both professional APCs and tumor cells. Cross-
presentation of Ag delivered to dendritic cells (DCs) 
by BGs can activate both CD4+ and CD8+ T cells 
and stimulate the immune system to enhance the 
immune response against Ag expressed by target 
cells. Inner and outer membrane structures of BGs 
including lipopolysaccharide (LPS) and other 
PAMPs remain intact after protein E-mediated lysis 
of Gram-negative bacteria. Thus, beside possessing a 
high loading capacity; BGs carry highly effective 
molecules for the stimulation of cross presentation 
by DCs on their surface, specially, tumor-associated 
antigens (TAAs). BGs with their intact envelope 
structures are not only immune stimulatory to 
professional phagocytes but are also capable of 
providing stimulatory signals to tumor cells. It is 
known that melanoma cells have the capacity to 
behave as non-professional APCs and can phagocyte 
both apoptotic and live cells, and it was recently 
shown that melanoma cells actively respond to 
exposure to BGs by increasing their rate of 
phagocytosis. Using BGs for gene delivery to the 
immunocompetent cells, in particular DCs as well as 
tumor cells, could initiate or restore the immune 
response against the delivered TAAs as well as 
induce and increase the expression of target genes by 
APCs and tumor cells (14). 
www.thecancerpress.com 
Vol. 2, No.1, February, 2016 
Afkhami and Matin, 2016. The Cancer Press, 2(1): 8-11                                                                                                                          10 
www.imaqpress.com  
www.thecancerpress.com 
 
Conclusions 
These observations indicate high capacity of BGs to target various histological types of cancers. Bacterial 
ghosts are very useful non-living carriers, as they can carry foreign antigens, nucleic acids and drugs in 
one or more cellular locations simultaneously. Optimization and improvement of the selected prospective 
model type of BGs would help to progress the development of microbial-mediated disease treatment and 
drug delivery systems and their application in future clinical trials. 
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